Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301 / Diab, A; Ascierto, Pa; Maio, M; Abdel-Wahab, R; Negrier, S; Mortier, L; Arenberger, P; Dalle, S; Krajsova, I; De La Cruz, L; Leccia, Mt; Guida, M; Lebbe, C; Grob, Jj; Butler, Mo; In, Gk; Loquai, C; Walker, Jwt; Atkinson, V; Kapiteijn, E; Haferkamp, S; Chunduru, S; Rahimian, S; Guidoboni, M; Robert, C. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 43:23(2025). [10.1200/JCO-25-01412]

Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301

Ascierto PA;
2025

2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301 / Diab, A; Ascierto, Pa; Maio, M; Abdel-Wahab, R; Negrier, S; Mortier, L; Arenberger, P; Dalle, S; Krajsova, I; De La Cruz, L; Leccia, Mt; Guida, M; Lebbe, C; Grob, Jj; Butler, Mo; In, Gk; Loquai, C; Walker, Jwt; Atkinson, V; Kapiteijn, E; Haferkamp, S; Chunduru, S; Rahimian, S; Guidoboni, M; Robert, C. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 43:23(2025). [10.1200/JCO-25-01412]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1017226
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact